Research programme: trivalent recombinant human influenza subunit vaccine - Cilian

Drug Profile

Research programme: trivalent recombinant human influenza subunit vaccine - Cilian

Alternative Names: CiFlu; Glide influenza virus vaccine

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cilian
  • Developer Cilian; Glide Technologies
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Germany (Parenteral)
  • 21 Sep 2015 Cilian and Glide Technologies agree to develop a solid formulation of CiFlu® for Influenza virus infections
  • 21 Sep 2015 Early research in Influenza virus infections in Germany (PO) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top